October 2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory cannabinoid ligands is available, which has led to considerable advancements in the understanding of CB2 However, until recently, most CB2 ligands were highly lipophilic and as such not optimal for clinical A number of strategies have been applied to develop CB2 ligands to achieve closer to 'drug-like' properties

August 2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though Promising preclinical data support the applicability of CB2 activation in autoimmune and inflammatory cannabinoid ligands is available, which has led to considerable advancements in the understanding of CB2 However, until recently, most CB2 ligands were highly lipophilic and as such, not optimal for clinical A number of strategies have been applied to develop CB2 ligands to achieve closer to 'drug-like' properties

target for regulating schizophrenia-relevant brain circuits "Although the cannabinoid type-2 receptor (CB2 ) is highly expressed in the immune system, emerging evidence points to CB2 playing a key role in regulating Recent anatomical studies, combined with electrophysiological studies, indicate that CB2 receptors are effects of CB2 receptor activation, make this receptor an intriguing target for treating schizophrenia The development of new CB2-related pharmacological and genetic tools, including the first small molecule

In addition, co-treatment of a CB2 antagonist with THC, and a CB2 agonist with CBD, reversed the impact In conclusion, 10μM THC and CBD altered the differentiation of HC11 cells, in part via the CB2 receptor

receptors by different types of ligands, as well as the differences between CB1 and its homologous, the CB2

And A1, A2A, and CB2 activation by agonists has protective functions on noise- or drug-induced hearing

treatment RAMP and MRAP accessory proteins have selective effects on expression and signalling of the CB1, CB2 autism GPCRs in Oncology and Immunology Emerging GPCR targets for AUD: Insights from preclinical studies CB2

Classified GPCR News  from August 19th to 25th, 2024 GPCR Activation and Signaling Homodimerization of CB2

predominantly arises via engagement with the principal two G-protein-coupled cannabinoid receptors, CB1 and CB2

substituted alkylindoles that activate G protein-coupled receptors distinct from the cannabinoid CB1 and CB2

Vibrational Energy Landscapes and Energy Flow in GPCRs Allosterism in the adenosine A2A and cannabinoid CB2

pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB2

Structural and Molecular Insights into GPCR Function Structural basis of selective cannabinoid CB2 receptor

disorders Discovery of a Photoaffinity Probe that Captures the Active Conformation of the Cannabinoid CB2

potential in neurodegenerative diseases The progress of small molecules against cannabinoid 2 receptor (CB2R

design and in vivo application of optogenetically functionalized Drosophila dopamine receptors Targeting CB2R